Still, considering that heterozygous mutations show intermediate effects, and the possibility that common variant carriers have diminished TREM2 function by unknown mechanisms, it is reasonable to speculate that increased TREM2 activity above baseline may be beneficial, and that the approximately twofold increase in cell surface TREM2 that we observed with MEK inhibition may be significant.
1
—
—